Mark Rogers‐Evans - Concepedia

Author

Mark Rogers‐Evans

Roche (Switzerland)

Also Known As

M Rogers-Evans, M Rogers‐Evans, M. ROGERS‐EVANS, Mark Rogers-Evans, Mark Rogers‐Evans

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)ETH Zurich Dalhousie University University of Bristol

About

Mark Rogers‐Evans is an author at Roche (Switzerland) specializing in pharmacology, drug discovery, and medicinal chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.6K
2	Natural Sciences	14	16	1.3K
3	Biochemistry	12	12	1.1K
4	Engineering	9	9	577
5	Biomedical Engineering	1	1	49

Mark Rogers‐Evans

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Oxetanes in Drug Discovery: Structural and Synthetic Insights Georg Wuitschik, Erick M. Carreira, Björn Wagner, Journal of Medicinal Chemistry Medicinal ChemistryHeterocyclicBiochemistryNatural SciencesMedicine	2010	402
Oxetanes as Promising Modules in Drug Discovery Georg Wuitschik, Mark Rogers‐Evans, Klaus Müller, Angewandte Chemie International Edition Drug TargetBioorganic ChemistryOrganic ChemistryChemical BiologyRedox Biology	2006	255
Development of a Virtual Screening Method for Identification of “Frequent Hitters” in Compound Libraries Olivier Roche, Petra Schneider, Jochen Zuegge, Journal of Medicinal Chemistry EngineeringHit IdentificationPattern DiscoveryNonlinear Statistical MethodsMedicinal Chemistry	2001	250
Spirocyclic Oxetanes: Synthesis and Properties Georg Wuitschik, Mark Rogers‐Evans, A. Buckl, Angewandte Chemie International Edition	2008	221
β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease Hans Hilpert, Wolfgang Guba, Thomas J. Woltering, Journal of Medicinal Chemistry Neurochemical BiomarkersPharmacotherapyAlzheimer ’Pre-clinical PharmacologyMolecular Pharmacology	2013	136
Synthesis and Structural Analysis of a New Class of Azaspiro[3.3]heptanes as Building Blocks for Medicinal Chemistry Johannes A. Burkhard, Carine Guérot, Henner Knust, Organic Letters Combinatorial ChemistryBuilding BlocksMedicinal ChemistryEngineeringHeterocyclic	2010	116
Biochemical and behavioural characterization of EMPA, a novel high‐affinity, selective antagonist for the OX<sub>2</sub> receptor P. Malherbe, Edilio Borroni, Luca Gobbi, British Journal of Pharmacology	2009	92
A Concise Asymmetric Route to the Bridged Bicyclic Tropane Alkaloid Ferruginine Using Enyne Ring-Closing Metathesis Varinder K. Aggarwal, Christopher J. Astle, Mark Rogers‐Evans Organic Letters Short Asymmetric SynthesisCross-coupling ReactionEngineeringAlkene MetathesisOrganic Chemistry	2004	76
Synthesis and Stability of Oxetane Analogs of Thalidomide and Lenalidomide Johannes A. Burkhard, Georg Wuitschik, Jean‐Marc Plancher, Organic Letters Human Plasma StabilityPharmaceutical ScienceOxetane AnalogsOrganic ChemistryPharmacotherapy	2013	76
Oxetanes as Promising Modules in Drug Discovery Georg Wuitschik, Mark Rogers‐Evans, Klaus Müller, Angewandte Chemie Medicinal ChemistryDrug TargetBioorganic ChemistryLiegenden GerüstsBiochemistry	2006	65

Page 1